<DOC>
	<DOCNO>NCT00334321</DOCNO>
	<brief_summary>This study evaluate feasibility use helical tomotherapy deliver IMRT post-hysterectomy endometrial cancer patient receive adjuvant radiotherapy .</brief_summary>
	<brief_title>Pelvic IMRT With Tomotherapy Post-Hysterectomy Endometrial Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Age great equal 18 year age 2 . Karnofsky Performance Status great equal 60 3 . FIGO Surgical Stage I , II , III 4 . Pathologic confirmation endometrial cancer 5 . Patient status post hysterectomy 6 . Patients local regional metastasis eligible protocol , distant metastases 7 . Patients must adequate : Bone Marrow Function : ANC ≥ 1,500/mcl ( &lt; CTCAE v 3.0 Grade 1 ) . Platelets ≥ 100,000/mcl ( &lt; CTCAE v3.0 Grade 1 ) . Renal Function : Serum creatinine ≤ institutional upper limit normal ( ULN ) ( CTCAE v 3.0 Grade 0 ) . Note : serum creatinine &gt; ULN , 24hour creatinine clearance must collect must &gt; 50 mL/min . Hepatic Function : Bilirubin ≤ 1.5 x ULN ( &lt; CTCAE v 3.0 Grade 1 ) . SGOT≤ 2.5 x ULN ( &lt; CTCAE v 3.0 Grade 1 ) . Alkaline phosphatase ≤ 2.5 x ULN ( &lt; CTCAE v 3.0 Grade 1 ) . Neurologic Function : Neuropathy ( sensory motor ) &lt; CTCAE v 3.0 Grade 1 . 1 . Age le 18 year age 2 . Karnofsky Performance Status less 60 3 . Radiographic pathologic evidence metastatic disease ( pelvic paraaortic lymph node ) 4 . Prior pelvic radiation therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>IMRT</keyword>
	<keyword>Tomotherapy</keyword>
	<keyword>Post-Hysterectomy</keyword>
	<keyword>Endometrial Cancer</keyword>
</DOC>